Matches in SemOpenAlex for { <https://semopenalex.org/work/W3006909418> ?p ?o ?g. }
- W3006909418 abstract "Abstract Background The HER2 extracellular domain shed in blood (HER2 ECD ) is reported to rise and fall in parallel with HER2+ breast cancer behavior. In this study, we evaluated the clinical relevance of plasma HER2 ECD values in patients with metastatic breast cancer treated in the SAKK22/99 trial comparing trastuzumab monotherapy followed by trastuzumab-chemotherapy combination at progression versus upfront combination therapy. Methods Quantitative assessment of plasma HER2 ECD was performed in 133 patients at baseline; after 2–24 h; at 3 weeks; at first response evaluation (8–9 weeks); and at tumor progression. Associations with tumor characteristics, disease course and trial treatment were evaluated. Results Baseline HER2 ECD levels were stable within 24 h after the first trastuzumab injection. These plasma values correlated positively with the HER2 gene ratio (r s = 0.39, P < 0.001) and HER2 protein expression levels (r s = 0.36, P < 0.001) but not with ER/PR status of the primary tumor. HER2 ECD baseline levels were positively associated with the presence of visceral disease ( P = 0.05) and poor patients’ outcome (Cox-regression: P = 0.009). Patients with high baseline levels ( > 35 ng/ml) had the worst overall survival ( P = 0.03) if treated with upfront combination therapy. Conversely, patients with low HER2 ECD baseline values (< 15 ng/ml) had longer time to progression on combined trastuzumab-chemotherapy when first treated with trastuzumab monotherapy ( P = 0.02). Monitoring HER2 ECD levels during the course of the trial revealed significant time ( P = 0.001) and time-treatment arm interactions ( P = 0.0007). Under upfront trastuzumab alone, the HER2 ECD levels remained stable until just before disease progression. In patients responding to combination treatment HER2 ECD levels decreased to > 20%. Conclusions Plasma HER2 ECD levels in patients with metastatic breast cancer reflect HER2 disease status. This robust biomarker might help identifying patients without visceral disease profiting from a sequential treatment’s modality. Monitoring HER2 ECD levels during trastuzumab monotherapy could help defining the optimal time to introduce chemotherapy. Trial registration Registration Number by ClinicalTrials.gov: NCT00004935 , Trial number: SAKK22/99. Registered on 27 January 2003." @default.
- W3006909418 created "2020-03-06" @default.
- W3006909418 creator A5006229315 @default.
- W3006909418 creator A5031581462 @default.
- W3006909418 creator A5031592069 @default.
- W3006909418 creator A5044589331 @default.
- W3006909418 creator A5061473697 @default.
- W3006909418 creator A5061698687 @default.
- W3006909418 creator A5065813790 @default.
- W3006909418 creator A5070351685 @default.
- W3006909418 date "2020-02-11" @default.
- W3006909418 modified "2023-09-30" @default.
- W3006909418 title "Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: results of a randomized study - SAKK 22/99" @default.
- W3006909418 cites W1763604934 @default.
- W3006909418 cites W1971481885 @default.
- W3006909418 cites W1986291899 @default.
- W3006909418 cites W1987380783 @default.
- W3006909418 cites W1988610380 @default.
- W3006909418 cites W2024032315 @default.
- W3006909418 cites W2024896551 @default.
- W3006909418 cites W2044702943 @default.
- W3006909418 cites W2075075174 @default.
- W3006909418 cites W2077778212 @default.
- W3006909418 cites W2087868278 @default.
- W3006909418 cites W2096205264 @default.
- W3006909418 cites W2097255042 @default.
- W3006909418 cites W2099117820 @default.
- W3006909418 cites W2123299533 @default.
- W3006909418 cites W2128179232 @default.
- W3006909418 cites W2154655712 @default.
- W3006909418 cites W2163873687 @default.
- W3006909418 cites W2168953808 @default.
- W3006909418 cites W2259802687 @default.
- W3006909418 cites W2560635244 @default.
- W3006909418 cites W2567078974 @default.
- W3006909418 cites W2757511999 @default.
- W3006909418 cites W2792392509 @default.
- W3006909418 cites W2889232066 @default.
- W3006909418 cites W2904225773 @default.
- W3006909418 doi "https://doi.org/10.1186/s12885-020-6594-0" @default.
- W3006909418 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7014942" @default.
- W3006909418 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32046665" @default.
- W3006909418 hasPublicationYear "2020" @default.
- W3006909418 type Work @default.
- W3006909418 sameAs 3006909418 @default.
- W3006909418 citedByCount "6" @default.
- W3006909418 countsByYear W30069094182020 @default.
- W3006909418 countsByYear W30069094182021 @default.
- W3006909418 countsByYear W30069094182022 @default.
- W3006909418 countsByYear W30069094182023 @default.
- W3006909418 crossrefType "journal-article" @default.
- W3006909418 hasAuthorship W3006909418A5006229315 @default.
- W3006909418 hasAuthorship W3006909418A5031581462 @default.
- W3006909418 hasAuthorship W3006909418A5031592069 @default.
- W3006909418 hasAuthorship W3006909418A5044589331 @default.
- W3006909418 hasAuthorship W3006909418A5061473697 @default.
- W3006909418 hasAuthorship W3006909418A5061698687 @default.
- W3006909418 hasAuthorship W3006909418A5065813790 @default.
- W3006909418 hasAuthorship W3006909418A5070351685 @default.
- W3006909418 hasBestOaLocation W30069094181 @default.
- W3006909418 hasConcept C121608353 @default.
- W3006909418 hasConcept C126322002 @default.
- W3006909418 hasConcept C143998085 @default.
- W3006909418 hasConcept C2775930923 @default.
- W3006909418 hasConcept C2776694085 @default.
- W3006909418 hasConcept C2779786085 @default.
- W3006909418 hasConcept C2780140570 @default.
- W3006909418 hasConcept C50382708 @default.
- W3006909418 hasConcept C530470458 @default.
- W3006909418 hasConcept C71924100 @default.
- W3006909418 hasConceptScore W3006909418C121608353 @default.
- W3006909418 hasConceptScore W3006909418C126322002 @default.
- W3006909418 hasConceptScore W3006909418C143998085 @default.
- W3006909418 hasConceptScore W3006909418C2775930923 @default.
- W3006909418 hasConceptScore W3006909418C2776694085 @default.
- W3006909418 hasConceptScore W3006909418C2779786085 @default.
- W3006909418 hasConceptScore W3006909418C2780140570 @default.
- W3006909418 hasConceptScore W3006909418C50382708 @default.
- W3006909418 hasConceptScore W3006909418C530470458 @default.
- W3006909418 hasConceptScore W3006909418C71924100 @default.
- W3006909418 hasFunder F4320327373 @default.
- W3006909418 hasIssue "1" @default.
- W3006909418 hasLocation W30069094181 @default.
- W3006909418 hasLocation W30069094182 @default.
- W3006909418 hasLocation W30069094183 @default.
- W3006909418 hasLocation W30069094184 @default.
- W3006909418 hasLocation W30069094185 @default.
- W3006909418 hasLocation W30069094186 @default.
- W3006909418 hasLocation W30069094187 @default.
- W3006909418 hasLocation W30069094188 @default.
- W3006909418 hasOpenAccess W3006909418 @default.
- W3006909418 hasPrimaryLocation W30069094181 @default.
- W3006909418 hasRelatedWork W2001196910 @default.
- W3006909418 hasRelatedWork W2030434439 @default.
- W3006909418 hasRelatedWork W2050439103 @default.
- W3006909418 hasRelatedWork W2069163378 @default.
- W3006909418 hasRelatedWork W2130521606 @default.
- W3006909418 hasRelatedWork W2218005127 @default.
- W3006909418 hasRelatedWork W2934076975 @default.
- W3006909418 hasRelatedWork W4253790588 @default.